Advertisement

Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders

  • Barbara Illowsky KarpEmail author
  • Hannah Tandon
  • Deionna Vigil
  • Pamela Stratton
Review Article

Abstract

Introduction and hypothesis

Botulinum toxin (BoNT) is increasingly used for pain, especially with muscle spasm. We describe our methodology for BoNT treatment of chronic pelvic pain (CPP) in women and place it in the context of the literature on techniques for this use.

Methods

Databases were searched using terms “botulinum toxin,” “pelvic pain,” and “vaginismus.” Reports on vaginismus/vulvodynia/vestibulodynia (included if pelvic floor muscles were injected) were grouped as “vaginismus/vulvar pain disorders” (V/VPD). We analyzed the type of report, condition, toxin serotype/brand, dose/dilution, muscle selection, guidance technique, and anesthesia. Publications from the same authors without unique information were combined for specific analyses.

Results

Thirty-eight reports had analyzable information; many lacked complete information. Most were open-label prospective reports; there were four technical reports, one randomized comparison of doses and one placebo-controlled study of efficacy. Pelvic floor muscles were approached transvaginally, transperineally or transgluteally. BoNT brand/dose/dilution varied widely. Muscle localization techniques included anatomical landmarks only, electromyography, electrical stimulation with/without ultrasound, and fluoroscopy/CT scanning. Papers discussing analgesia utilized general anesthesia, conscious sedation with/without topical/local anesthesia, topical/local agent alone or pudendal block before or after injection. Cumulatively, 58–100% of patients with CPP and 71–100% of those with V/VPD improved. Serious adverse events (transient fecal incontinence/constipation, urinary incontinence/retention) were more frequent with higher doses.

Conclusions

BoNT can be safely and tolerably injected into pelvic floor muscles in women as an out-patient procedure. This study identifies methodological factors to be considered in future studies and the critical need for high-quality clinical trials for this emerging treatment.

Keywords

Botulinum toxin Chemodenervation Chronic pelvic pain Pelvic floor spasm Pelvic pain Vaginismus 

Notes

Source of funding

This research was supported by the Intramural Research Program of the National Institutes of Health.

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflicts of interest related to this article.

Disclosures

Dr Karp, Dr Stratton are investigators and Ms Tandon was a research assistant on a different study for which the National Institutes of Health received a grant from Allergan, Inc, the manufacturer of onabotulinumtoxinA (Botox). Dr Karp is also an associate investigator on one study for which the Icahn School of Medicine at Mt Sinai received a grant from Allergan, Inc, and another study for which the National Institutes of Health received a grant from Merz, Inc, the manufacturer of incobotulinumtoxinA (Xeomin). Ms Vigil has no disclosures.

References

  1. 1.
    Ahangari A. Prevalence of chronic pelvic pain among women: an updated review. Pain Physician. 2014;17:E141–7.PubMedGoogle Scholar
  2. 2.
    Engeler DS, Baranowski AP, Dinis-Oliveira P, et al. The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. Eur Urol. 2013;64:431–9.CrossRefGoogle Scholar
  3. 3.
    Twiddy H, Bradshaw A, Chawla R, Johnson S, Lane N. Female chronic pelvic pain: the journey to diagnosis and beyond. Pain Manag. 2017;7:155–9.CrossRefGoogle Scholar
  4. 4.
    Stratton P, Khachikyan I, Sinaii N, Ortiz R, Shah J. Association of chronic pelvic pain and endometriosis with signs of sensitization and myofascial pain. Obstet Gynecol. 2015;125:719–28.CrossRefGoogle Scholar
  5. 5.
    Levesque A, Riant T, Ploteau S, Rigaud J, Labat JJ. Clinical criteria of central sensitization in chronic pelvic and perineal pain (convergences PP criteria): elaboration of a clinical evaluation tool based on formal expert consensus. Pain Med. 2018;19:2009–15.CrossRefGoogle Scholar
  6. 6.
    Hoffman D. Central and peripheral pain generators in women with chronic pelvic pain: patient centered assessment and treatment. Curr Rheumatol Rev. 2015;11:146–66.CrossRefGoogle Scholar
  7. 7.
    Reissing ED, Brown C, Lord MJ, Binik YM, Khalife S. Pelvic floor muscle functioning in women with vulvar vestibulitis syndrome. J Psychosom Obstet Gynaecol. 2005;26:107–13.CrossRefGoogle Scholar
  8. 8.
    Stratton P, Berkley KJ. Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications. Hum Reprod Update. 2011;17:327–46.CrossRefGoogle Scholar
  9. 9.
    Aredo JV, Heyrana KJ, Karp BI, Shah JP, Stratton P. Relating chronic pelvic pain and endometriosis to signs of sensitization and myofascial pain and dysfunction. Semin Reprod Med. 2017;35:88–97.CrossRefGoogle Scholar
  10. 10.
    Zhang Z, Zolnoun DA, Francisco EM, Holden JK, Dennis RG, Tommerdahl M. Altered central sensitization in subgroups of women with vulvodynia. Clin J Pain. 2011;27:755–63.CrossRefGoogle Scholar
  11. 11.
    Sadownik LA. Etiology, diagnosis, and clinical management of vulvodynia. Int J Womens Health. 2014;6:437–49.CrossRefGoogle Scholar
  12. 12.
    Shah JP, Gilliams EA. Uncovering the biochemical milieu of myofascial trigger points using in vivo microdialysis: an application of muscle pain concepts to myofascial pain syndrome. J Bodyw Mov Ther. 2008;12:371–84.CrossRefGoogle Scholar
  13. 13.
    Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin a. Parkinsonism Relat Disord. 2011;17(Suppl 1):S28–33.CrossRefGoogle Scholar
  14. 14.
    Park J, Chung ME. Botulinum toxin for central neuropathic pain. Toxins (Basel). 2018;10:224.  https://doi.org/10.3390/toxins10060224.CrossRefGoogle Scholar
  15. 15.
    Escher CM, Paracka L, Dressler D, Kollewe K. Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Ther Adv Neurol Disord. 2017;10:127–35.CrossRefGoogle Scholar
  16. 16.
    Sandrini G, De Icco R, Tassorelli C, Smania N, Tamburin S. Botulinum neurotoxin type a for the treatment of pain: not just in migraine and trigeminal neuralgia. J Headache Pain. 2017;18:38.CrossRefGoogle Scholar
  17. 17.
    Safarpour Y, Jabbari B. Botulinum toxin treatment of pain syndromes -an evidence based review. Toxicon. 2018;147:120–8.CrossRefGoogle Scholar
  18. 18.
    Matak I, Lackovic Z. Botulinum toxin A, brain and pain. Prog Neurobiol. 2014;119-120:39–59.Google Scholar
  19. 19.
    Brin MF, Vapnek JM. Treatment of vaginismus with botulinum toxin injections. Lancet. 1997;349:252–3.CrossRefGoogle Scholar
  20. 20.
    Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG. Pilot study of botulinum toxin type a in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol. 2004;44:46–50.CrossRefGoogle Scholar
  21. 21.
    Thomson AJ, Jarvis SK, Lenart M, Abbott JA, Vancaillie TG. The use of botulinum toxin type a (BOTOX) as treatment for intractable chronic pelvic pain associated with spasm of the levator ani muscles. BJOG. 2005;112:247–9.CrossRefGoogle Scholar
  22. 22.
    Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol. 2006;108:915–23.CrossRefGoogle Scholar
  23. 23.
    Stratton P, Tandon H, Sinaii N, Shah J, Karp BI. Botulinum toxin for chronic pelvic pain in endometriosis. World Congress on Endometriosis. Vancouver, B.C. 2017.Google Scholar
  24. 24.
    Nesbitt-Hawes EM, Won H, Jarvis SK, Lyons SD, Vancaillie TG, Abbott JA. Improvement in pelvic pain with botulinum toxin type A—single vs. repeat injections. Toxicon. 2013;63:83–7.CrossRefGoogle Scholar
  25. 25.
    Nesbitt-Hawes EM, Dietz HP, Abbott JA. Four-dimensional ultrasound guidance for pelvic floor Botulinum toxin-A injection in chronic pelvic pain: a novel technique. Ultrasound Obstet Gynecol. 2018;51:396–400.CrossRefGoogle Scholar
  26. 26.
    Adelowo A, Hacker MR, Shapiro A, Modest AM, Elkadry E. Botulinum toxin type A (BOTOX) for refractory myofascial pelvic pain. Female Pelvic Med Reconstr Surg. 2013;19:288–92.CrossRefGoogle Scholar
  27. 27.
    Bautrant E, Quintas-Marquès L, Eggermont J, et al. Use of botulinum neurotoxin type A (Xeomin) injections to the perineal muscles in cases of perineal pain and dysfunction associated with pelvic floor muscle overcontraction and myalgia. Toxicon. 2015;93:S7–8.CrossRefGoogle Scholar
  28. 28.
    Bertolasi L, Frasson E, Cappelletti JY, Vicentini S, Bordignon M, Graziottin A. Botulinum neurotoxin type A injections for vaginismus secondary to vulvar vestibulitis syndrome. Obstet Gynecol. 2009;114:1008–16.CrossRefGoogle Scholar
  29. 29.
    Bhide A, Bray R, Gopalan V, Fernando R, Khullar V, Digesu A. To assess whether botulinum type A toxin injection to the pelvic floor improves symptoms and quality of life in women with chronic pelvic pain (CPP) due to pelvic floor muscle hyperalgesia. Neurourol Urodyn. 2014;33:1025.Google Scholar
  30. 30.
    Brown CS, Glazer HI, Vogt V, Menkes D, Bachmann G. Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. J Reprod Med. 2006;51:635–41.PubMedGoogle Scholar
  31. 31.
    Brueseke TJ, Lane FL. Ischiorectal fossa abscess after pelvic floor injection of botulinum toxin. Am J Obstet Gynecol. 2012;206:e7–8.CrossRefGoogle Scholar
  32. 32.
    Dykstra DD, Presthus J. Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study. J Reprod Med. 2006;51:467–70.PubMedGoogle Scholar
  33. 33.
    El-Khawand D, Wehbe S, O'Hare P, et al. Botulinum toxin a injections into pelvic floor muscles under electromyographic guidance for women with refractory high tone pelvic floor dysfunction: three-month follow-up data of an ongoing pilot study. Neurourol Urodyn. 2013;32:117.Google Scholar
  34. 34.
    Morrissey D, El-Khawand D, Ginzburg N, Wehbe S, O'Hare P III, Whitmore K. Botulinum toxin A injections into pelvic floor muscles under electromyographic guidance for women with refractory high-tone pelvic floor dysfunction: a 6-month prospective pilot study. Female Pelvic Med Reconstr Surg. 2015;21:277–82.CrossRefGoogle Scholar
  35. 35.
    Evans SF, Porter JM. Simplified technique for injection of botulinum toxin to obturator internus muscle using ultrasound-guided nerve stimulation for persistent pelvic pain. Aust N Z J Obstet Gynaecol. 2015;55:612–4.CrossRefGoogle Scholar
  36. 36.
    Fageeh WM. Different treatment modalities for refractory vaginismus in western Saudi Arabia. J Sex Med. 2011;8:1735–9.CrossRefGoogle Scholar
  37. 37.
    Gajraj NM. Botulinum toxin A injection of the obturator internus muscle for chronic perineal pain. J Pain. 2005;6:333–7.CrossRefGoogle Scholar
  38. 38.
    Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol. 2004;104:922–5.CrossRefGoogle Scholar
  39. 39.
    Ghazizadeh S, Abedi J, Pourmatroud AJ, Raiisi F, Lesanpezeshki M. Comparison of 500 units vs 250 units of botulinum toxin (abobotulinumtoxinA) for the treatment of severe vaginismus. J Bacteriol Mycol. 2016;3:1033–6.Google Scholar
  40. 40.
    Goldstein AT, Burrows LJ, Kellogg-Spadt S. Intralevator injection of botulinum toxin for the treatment of hypertonic pelvic floor muscle dysfunction and vestibulodynia. J Sex Med. 2011;8:1287–90.CrossRefGoogle Scholar
  41. 41.
    Greenleaf BA, McKinney TB, Greenleaf BA, et al. Vaginismus and botulinum toxin a: A measurement of treatment. Female Pelvic Med Reconstr Surg. 2011;17:S93.Google Scholar
  42. 42.
    Halder GE, Scott L, Wyman AM, Mora N, Bassaly R, Hoyte L. Botox with physical therapy for myofascial pelvic pain. Female Pelvic Med Reconstr Surg. 2015;21:S143.Google Scholar
  43. 43.
    Halder GE, Scott L, Wyman A, et al. Botox combined with myofascial release physical therapy as a treatment for myofascial pelvic pain. Investig Clin Urol. 2017;58:134–9.CrossRefGoogle Scholar
  44. 44.
    Kieger A, Marker D, Hong K. CT-guided intramuscular Botox injection and the evolving chronic pelvic pain practice paradigm. J Vasc Interv Radiol. 2016;27:S262.CrossRefGoogle Scholar
  45. 45.
    Zavridis P, Moreland A, Minwell G, Kieger A, Yim D, Hong K. Safety and early results of CT-guided intramuscular injection of botulinum toxin-A for the management of myofascial pelvic pain. Reg Anesth Pain Med. 2016;41:e118.CrossRefGoogle Scholar
  46. 46.
    Moreland A, Minwell G, Kieger A, Yim D, Hong K. CT-guided intramuscular injection of botulinum toxin A for treatment of myofascial pelvic pain: single center evaluation of safety and early efficacy (abstract). Radiol Soc N Amer 2016 Scientific Assembly and Annual Meeting, November 27–December 2, 2016, Chicago IL. 2016. archive.rsna.org/2016/16003493.html. Accessed 27 February 2017.
  47. 47.
    Moldwin RM, Fariello JY. Myofascial trigger points of the pelvic floor: associations with urological pain syndromes and treatment strategies including injection therapy. Curr Urol Rep. 2013;14:409–17.CrossRefGoogle Scholar
  48. 48.
    Orasanu B, Guetzko ME, Mahajan S. Myobloc® for the treatment of myofascial pelvic pain secondary resistant to Botox®. Female Pelvic Med Reconstr Surg. 2013;19:S114.Google Scholar
  49. 49.
    Pacik PT. Botox treatment for vaginismus. Plast Reconstr Surg. 2009;124:455e–6e.CrossRefGoogle Scholar
  50. 50.
    Pacik PT, Geletta S. Vaginismus treatment: clinical trials follow up 241 patients. Sex Med. 2017;5:e114–23.CrossRefGoogle Scholar
  51. 51.
    Pacik PT, Geletta S. OnabotulinumtoxinA as part of a multimodal program to treat vaginismus. J Appl Biobehav Res. 2015;20:25–36.CrossRefGoogle Scholar
  52. 52.
    Park AJ, Paraiso MF. Successful use of botulinum toxin type A in the treatment of refractory postoperative dyspareunia. Obstet Gynecol. 2009;114:484–7.CrossRefGoogle Scholar
  53. 53.
    Pope RJ, Mahajan S. Onabotulinum toxin A for myalgia of multiple sites including the vagina. Female Pelvic Med Reconstr Surg. 2013;19:S179.CrossRefGoogle Scholar
  54. 54.
    Quirino W, James RL, Mahajan ST. Pelvic floor botulinum a toxin injection for the treatment of myofascial pelvic pain. J Pelvic Med Surg. 2010;16:S164.Google Scholar
  55. 55.
    Romito S, Bottanelli M, Pellegrini M, Vicentini S, Rizzuto N, Bertolasi L. Botulinum toxin for the treatment of genital pain syndromes. Gynecol Obstet Investig. 2004;58:164–7.CrossRefGoogle Scholar
  56. 56.
    Yoon H, Chung WS, Shim BS. Botulinum toxin A for the management of vulvodynia. Int J Impot Res. 2007;19:84–7.CrossRefGoogle Scholar
  57. 57.
    Pacik P. Vaginismus: treatment using the botulinum toxin A program. J Sexual Med. 2013;10:177.Google Scholar
  58. 58.
    Pacik P. Vaginismus: treatment with intravaginal Botox and dilation under anesthesia. A prospective study of 70 consecutive patients. J Sex Med. 2011;8:64.Google Scholar
  59. 59.
    Bhide AA, Puccini F, Khullar V, Elneil S, Digesu GA. Botulinum neurotoxin type A injection of the pelvic floor muscle in pain due to spasticity: a review of the current literature. Int Urogynecol J. 2013;24:1429–34.CrossRefGoogle Scholar
  60. 60.
    Li M, Goldberger BA, Hopkins C. Fatal case of BOTOX-related anaphylaxis? J Forensic Sci. 2005;50:169–72.PubMedGoogle Scholar

Copyright information

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019

Authors and Affiliations

  1. 1.National Institute of Neurological Disorders and StrokeNational Institutes of HealthBethesdaUSA
  2. 2.Department of Rehabilitation MedicineNational Institutes of HealthBethesdaUSA
  3. 3.CarmelUSA

Personalised recommendations